Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Jerini’s Icatibant Falters in U.S., Wins In Europe

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA rejects orphan drug for hereditary angioedema, paving way for rivals to gain an edge.

Related Content

Shire Gets Advisory Committee Support For Firazyr Self-Administration Claim
FDA Asks If PRO Used For Shire's Firazyr Is Clinically Meaningful
Shire Seeks Advantage For Firazyr In HAE Through Self-Administration Data In Labeling
Shire Says Vpriv Is A Viable Option for Cerezyme Patients; Gets PDUFA For Firazyr
Shire Finally Able To Move Firazyr Forward
ViroPharma Gets Good News And Bad News On Cinryze From FDA
Dyax’s Acute HAE Candidate Faces Efficacy And Risk Hurdles At Panel Review
M&A Fireworks: Shire Buys Jerini For €328 Million
Jerini To Submit Complete Response Letter
With Few Questions From FDA, Cinryze Seems Set For Smooth Committee Review





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts